Detection of canine and equine procalcitonin for sepsis diagnosis in veterinary clinic by the development of novel MIP-based SPR biosensors
Graphical abstract
Introduction
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and represents the leading cause of morbidity and mortality from infection in humans as well as in veterinary patients, especially if not diagnosed and treated promptly [1,2]. The early diagnosis of sepsis and the evaluation of its severity are fundamental to prevent the onset of a septic shock and to increase the survival rate. Among the sepsis biomarkers (e.g. transcription factors, lactate, interleukins, C-reactive protein), PCT resulted to be a more specific indicator of bacterial infection or severity of infection, and to be a good control of the success of a therapeutic procedure [[3], [4], [5]]. The PCT level in serum of healthy donors is commonly below 0.05 ng mL−1, while it quickly increases up to 1.000 folds in serum from patients with sepsis, i.e. within 6–12 h [6]. While PCT immuno-based detection as sepsis predictor is assessed in humans, using reference commercial platforms (BRAHMS®, Vidas Biomerieux, etc.) [7], in veterinary patients there is a lack of validated assays [2,8] and, therefore, of clinical studies. The few available are mostly limited to dogs and horses. Moreover, in the last two decades several immuno-based Point of Care Tests have become available for human PCT detection, exclusively based on anti-calcitonin and anti-katacalcin antibodies, employing different detection strategies, i.e. type of signal recorded, its amplification strategy, and the platform adopted [[9], [10], [11], [12]]. In contrast to the high interest for labeled PCT immunoassays, in literature there are very few papers dedicated to label-free biosensors for PCT detection, and they all refer to human PCT with ng mL−1 detection levels and are mainly based on electrochemical transduction; Lim et al. (2017) synthesized as capturing agents, i.e. receptors, a series of synthetic peptides modified with cysteine residues at the C-terminus to facilitate thiol self-assembly, reporting a binding constant (Kd) of 0.39 ± 0.11 nM and limit of detection of 12.5 ng mL−1 for procalcitonin in PBS in the case of the BP3 peptide [13]. Electrochemical immunosensors are also reported, eventually using nanomaterials to achieve sensitive PCT detection. Li et al. (2015) described an immunosensor displaying a detection limit of 6 pg mL−1 for PCT using a new signal-amplification strategy based on a nanocomposite derived from amino-functionalized C60 nanoparticles, ferrocene carboxylic acid and platinum nanoparticles (PtNPs) [14]. Gao et al. (2020) developed a label-free electrochemical immunosensor using toluidine blue functionalized NiFe Prussian-blue analog nanocubes (NiFe PBA nanocubes@TB) as a signal amplifier. The developed immunosensor exhibited favorable performance for PCT detection with a linear range from 0.001 to 25 ng mL−1 and a detection limit of 3 × 10−4 ng mL−1 [15].
Beside electrochemical transduction, only one example of optical sensing is available in literature based on the use of biomimetic receptors. Sener et al. (2013) developed a molecularly imprinted polymer for the SPR-based detection of hPCT by using as functional monomers a solution of hydroxyethyl methacrylate (HEMA) and ethylene glycol dimethacrylate (EGDMA). As reported, the sensor accounted for a limit of detection of 9.9 ng mL−1 in both phosphate buffer and simulated blood plasma [16]. Conversely, in veterinary patients, only three commercial ELISA kits are available for dogs or horses, not fully validated, and suitable only for research purposes. In particular, only one ELISA-type immunoassay is reported in literature for equine PCT, based on human antibodies since there is no availability of specific antibodies [[17], [18], [19], [20], [21]].
In this framework, we considered the need to develop innovative biomimetic receptors to overcome limitations of current antibodies, i.e. availability, specificity, cost and stability. Molecularly Imprinted Polymers (MIPs) technology coupled to biosensing is particularly interesting thanks to its low-cost and long-term stability features [22]. In particular, macromolecules imprinting has received recently a growing interest despite the large size and the structural complexity of proteins (large number of functional groups) impeding molecules to penetrate the polymer network with consequences as nonspecific interactions, poor selectivity, and cross reactivity [23]. The choice of functional monomers defines the porous structure and the surface area of the MIP and plays an important role in the creation of binding sites [[24], [25], [26]]. Methacrylic acid and derivatives have been commonly used as functional monomers due to their structure related to polyethylene glycol (PEG), and to their characteristic being capable to act as a hydrogen-bond donor and acceptor [16,25,[27], [28], [29]]. Despite some good results, these monomers are not really suitable for biomolecules imprinting, presenting some limitations as the necessity of harsh conditions for polymerization and template removal, polymer hardness, and limited mechanical strength of such materials [30]. To overcome these drawbacks, recent research for functional monomers, that could positively influence the properties of the final polymer, led to a new generation of biopolymer-based MIPs. In this field, the neurotransmitters dopamine (DA) and, more recently, its structural analogous norepinephrine (NE) have emerged as very promising monomers for biomolecules imprinting. Due to the redox potential of the catechol moiety, the two catecholamines share the same ability to self-polymerize and to form adherent films on almost any kind of surface [31]. DA has already displayed excellent performances as a functional monomer for molecular imprinting technique, for the recognition and separation of small drugs, proteins, nucleic acids, and microorganisms [[32], [33], [34], [35], [36]]. Contrary to the impressive success of DA in molecular imprinting, its derivative NE, that differs from DA just for an additional hydroxyl group, has only recently been investigated as a new functional monomer for MIPs synthesis in biosensing [37]. In particular, Baldoneschi et al. reported on a polynorepinephrine (PNE)-based biosensor for the detection of troponin I, a crucial biomarker of acute myocardial infarction, coupled to SPR detection, highlighting the reduced non-specific adsorption of proteins on PNE with respect to polydopamine (PDA) on chip sensor surface [38]. Here, PNE and PDA were used and compared for the first time to produce MIPs able to bind and quantify canine and equine PCT. The MIPs have been characterized in terms of binding affinity toward the analyte, specificity, and sensitivity using real-time and label-free surface plasmon resonance (SPR) biosensing. Finally, the MIPs-based biosensors were tested on real canine and equine sera samples to evaluate its potential application for sepsis diagnosis in veterinary analysis.
Section snippets
Materials
Dopamine hydrochloride, ±-norepinephrine hydrochloride, tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), hydrochloric acid, acetic acid, sodium dodecyl sulphate (SDS), Tween-20, sodium chloride, mercaptohexanol, mercaptoundecanol and Amicon® Ultra filter were purchased from Merck (Italy). Bare gold sensor chips were purchased from GE Healthcare (Italy). Both recombinant canine procalcitonin and recombinant equine procalcitonin were purchased from Biovendor (Asheville, North Carolina,
MIP for canine procalcitonin
The binding characteristics of the canine and equine MIPs obtained by imprinting both PDA and PNE polymers were tested with Surface Plasmon Resonance (SPR) technology. Calibration curves with canine PCT (cPCT) protein (reconstituted in Tris-HCl 10 mmol L−1 pH 8.5, and diluted in TBST) were constructed. The MIP-cPCT binding was prompt, reaching a plateau stage of the SPR signal in less than 600 s. After each measurement, the MIP surface was fully regenerated (10 mmol L−1 HCl followed by 0.05%
Conclusions
The strong interest in human diagnosis of sepsis by detecting this biomarker is still poorly translated to veterinary application. Immuno-based assays are few, not validated, and almost exclusively based on the use of human anti-PCT antibodies. The successful development of two antibody-free, MIP-based SPR biosensors for the real-time and label free quantification of PCT in animal plasma, i.e. canine and equine, is described here. PDA and PNE biomimetic receptors for cPCT and ePCT were
Credit author statement
Federica Battaglia Conceptualization, Methodology, Investigation, Writing – original draft preparation, Writing – review & editing. Veronica Baldoneschi Investigation, Data curation, Writing – review & editing. Valentina Meucci Visualization, Writing – review & editing. Luigi Intorre Writing – review & editing, Supervision, Project administration, Funding acquisition. Maria Minunni Writing – review & editing, Supervision, Project administration, Funding acquisition. Simona Scarano
Ethics declarations
An owner's written consent was obtained for the collection of plasma for the horses and dogs included in this study.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References (40)
- et al.
The third international consensus definitions for sepsis and septic shock (Sepsis-3)
Jama
(2016) - et al.
Plasma procalcitonin concentrations are increased in dogs with sepsis
Vet Rec Open
(2018) - et al.
Intérets du dosage de procalcitonine en infectiologie
Immunoanal. Biol. Spéc.
(2001) - et al.
Comparison of procalcitonin and C-reactive protein as markers of sepsis
Crit. Care Med.
(2003) - et al.
Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department
Am. J. Clin. Pathol.
(2011) - et al.
Procalcitonin and the Calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors
J. Clin. Endocrinol. Metab.
(2004) - et al.
Comparison of the novel ARCHITECT procalcitonin assay with established procalcitonin assay systems
Pract. Lab. Med.
(2018) - et al.
The concentrations of the inflammatory markers the amino-terminal portion of C-type pronatriuretic peptide and procalcitonin in canine babesiosis caused by Babesia canis
Vet. Arh.
(2014) - et al.
A novel strategy of procalcitonin detection based on multi-nanomaterials of single-walled carbon nanohorns-hollow Pt nanospheres/PAMAM as signal tags
RSC Adv.
(2014) - et al.
Rapid and sensitive lateral flow immunoassay method for procalcitonin (PCT) based on time-resolved immunochromatography
Sensors
(2017)
Bifunctional gold nanoparticles as an agglomeration-enhancing tool for highly sensitive lateral flow tests: a case study with procalcitonin
Microchim. Acta
Controllable assembly of enzymes for multiplexed lab-on-a-chip bioassays with a tunable detection range
Angew. Chem. Int. Ed.
An electrochemical biosensor for detection of the sepsis-related biomarker procalcitonin
RSC Adv.
C60 carboxyfullerene-based functionalised nanohybrids as signal-amplifying tags for the ultrasensitive electrochemical detection of procalcitonin
Clin. Biochem.
An enzyme-free immunosensor for sensitive determination of procalcitonin using NiFe PBA nanocubes@TB as the sensing matrix
Anal. Chim. Acta
Rapid real-time detection of procalcitonin using a microcontact imprinted surface plasmon resonance biosensor
Analyst
Procalcitonin detection in veterinary species: investigation of commercial ELISA kits
Animals
Plasma procalcitonin concentration in healthy horses and horses affected by systemic inflammatory response syndrome
J. Vet. Intern. Med.
Investigation of a commercial ELISA for the detection of canine procalcitonin
J. Vet. Intern. Med.
A new ELISA for the quantification of equine procalcitonin in plasma as potential inflammation biomarker in horses
Anal. Bioanal. Chem.
Cited by (27)
Toward nano-sized imprinted norepinephrine-derived biopolymer as artificial receptors for detecting IgG1 by surface plasmon resonance
2024, Biosensors and BioelectronicsA LysLysLys-tag as trigger in polynorepinephrine epitope imprinting: The case study of soluble PD-L1 detection in serum by optical-based sensing
2023, Biosensors and BioelectronicsCitation Excerpt :Remarkable progress has recently been made in the preparation of imprinted polycatecholamines (pCAs)-based polymers for biomolecular recognition, mainly polydopamine (PDA) and polynorepinephrine (PNE), mimicking antibodies' natural binding (Baldoneschi et al., 2020; Battaglia et al., 2021; Palladino et al., 2018; Torrini et al., 2021; Yin et al., 2015).